Product
TAR-210
1 clinical trial
1 indication
Indication
Bladder CancerClinical trial
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR AlterationsStatus: Recruiting, Estimated PCD: 2028-06-28